side effects of glp-1 receptor agonists Your guide to GLP-1 side effects Clinical Recommendations to Manage Gastrointestinal
Description
Since obesity, insulin resistance, liver fat, and metabolic dysfunction are closely linked, GLP-1 and glucagon-based combinations are being studied for their potential to reduce liver fat, improve metabolic markers, and slow disease progression
X., Hu, N
4 Therefore, the use of a GLP-1 receptor agonist (exenatide, liraglutide) can be used as monotherapy or dual therapy in those with an A1C of 6.5% to 7.5%
According to the World Obesity Federations 2025 Atlas, the number of adults living with obesity is expected to more than double from 524 million in 2010 to 1.13 billion by 2030
